Evidence map›Paper›PMID 41816013›Full record

ReviewInternational journal of general medicine2026

Eosinophilic Heart Disease: Pathophysiology, Diagnosis, and Management - A Narrative Review.

Jing Dong, Haoran Fu, Na Wu, Liting Hu, Yinuo Du, Huhu Li, Li Liu

Abstract readReview
In one paragraph

Review in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jing Dong *Department of Cardiology, GenerTec Universal Xi'an Beihuan Hospital, The First Hospital of Xi'an Chanba International Port, Xi'an, Shaanxi Province, People's Republic of China.
Haoran Fu *Department of Cardiology, GenerTec Universal Xi'an Beihuan Hospital, The First Hospital of Xi'an Chanba International Port, Xi'an, Shaanxi Province, People's Republic of China.
Na WuDepartment of Cardiology, GenerTec Universal Xi'an Beihuan Hospital, The First Hospital of Xi'an Chanba International Port, Xi'an, Shaanxi Province, People's Republic of China.
Liting HuDepartment of Cardiology, GenerTec Universal Xi'an Beihuan Hospital, The First Hospital of Xi'an Chanba International Port, Xi'an, Shaanxi Province, People's Republic of China.
Yinuo DuDepartment of Cardiology, GenerTec Universal Xi'an Beihuan Hospital, The First Hospital of Xi'an Chanba International Port, Xi'an, Shaanxi Province, People's Republic of China.
Huhu LiDepartment of Cardiology, GenerTec Universal Xi'an Beihuan Hospital, The First Hospital of Xi'an Chanba International Port, Xi'an, Shaanxi Province, People's Republic of China.
Li LiuDepartment of Cardiology, GenerTec Universal Xi'an Beihuan Hospital, The First Hospital of Xi'an Chanba International Port, Xi'an, Shaanxi Province, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophilic heart disease (EHD) is an inflammatory cardiac disorder characterized by the infiltration and subsequent heart tissue damage mediated by eosinophils. The clinical manifestations of EHD vary widely, ranging from asymptomatic to severe, life-threatening conditions. Diagnosis relies on a multimodal approach, incorporating clinical presentations, laboratory findings (e.g. hypereosinophilia), and advanced imaging studies such as cardiac magnetic resonance imaging (MRI) and echocardiography. However, the gold standard for definitive diagnosis remains endomyocardial biopsy, which demonstrates eosinophilic infiltration and associated myocardial injury. Currently, there is no established consensus on specific therapeutic protocols for EHD. Management primarily targets the underlying etiology and mitigates eosinophil-induced cardiac damage. Prognosis is highly variable and largely dependent on the causative pathology, with outcomes spanning from rapidly progressive and fatal courses to indolent, chronic disease progression. Given the heterogeneity in clinical presentation and treatment responses, there is an urgent need for evidence-based clinical guidelines to standardize the management of EHD.

Indexed as

clinical presentationendomyocardial biopsyeosinophilic heart diseasehypereosinophiliaprognosis

Identifiers

PMID41816013
PMCPMC12973583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.